Data Sheet (Cat.No.T6250)



H-89 dihydrochloride

Chemical Properties


CAS No.: 130964-39-5

Formula: C20H20BrN3O2S·2HCl

Molecular Weight: 519.28

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	H-89 dihydrochloride (5-Isoquinolinesulfonamide) is a potent inhibitor of protein kinase A (PKA; IC50: $0.14~\mu M$, Ki: $48~nM$).			
Targets(IC50)	Autophagy,PKA,S6 Kinase			
In vitro	H-89 was shown to have a potent and selective inhibitory action against protein kinase A, with Ki of 0.048 microM. Pretreatment with H-89 led to a dose-dependent inhibition of the forskolin-induced protein phosphorylation, with no decrease in intracellular cyclic AMP levels in PC12D cells, and the NGF-induced protein phosphorylation was not inhibited. H-89 also significantly inhibited the forskolin-induced neurite outgrowth from PC12D cells. This inhibition also occurred when H-89 was added before the addition of dibutyryl cAMP. Pretreatment of PC12D cells with H-89 (30 microM) inhibited significantly cAMP-dependent histone IIb phosphorylation activity in cell lysates but did not affect other protein phosphorylation activity [1]. H-89 also inhibits S6K1, MSK1, ROCK-II, PKBa, and MAPKAP-K1b with IC50 values of 0.08, 0.12, 0.27, 2.6, and 2.8 µM, respectively [2]. In skinned EDL fibers of the rat, force responses to depolarization (by ion substitution) were inhibited only slightly by 10 microM H-89, a concentration more than sufficient to fully inhibit PKA. At 1-2 microM, H-89 significantly slowed the repriming rate in rat skinned fibers. With 100 microM H-89, the force response to depolarization by ion substitution was completely abolished. In intact single fibers of the flexor digitorum longus (FDB) muscle of the mouse, 1-3 microM H-89 had no noticeable effect on action-potential-mediated Ca2+ transients [3].			
In vivo	Different doses of H-89 (0.05, 0.1, 0.2 mg/100g) were administered intraperitoneally (i. p.), 30 min before intravenous (i.v.) infusion of PTZ (0.5% w/v). Intraperitoneal administration of H-89 (0.2 mg/100g) significantly increased seizure latency and threshold in PTZ-treated animals. Pretreatment of animals with PTX (50 and 100 mg/kg) attenuated the anticonvulsant effect of H-89 (0.2 mg/100g) in PTZ-exposed animals. H-89 (0.05, 0.2 mg/100g) prevented the epileptogenic activity of bucladesine (300 nM) with a significant increase of seizure latency and seizure threshold [4]. Treatment with H89 (10 mg/kg, administered i.p.) significantly inhibited AHR in OVA-sensitized/challenged mice, whereas it had no effect on airway responses in control mice. Treatment with H89 decreased eosinophil numbers by 80%, neutrophil numbers by 64% and lymphocyte numbers by 74% without any effect on macrophage. In the moderate model, the cell infiltrate consisted of 39.3% eosinophils, 58.5% macrophages, 1.9% neutrophils, and 0.3% lymphocytes and was entirely inhibited by H89 [5].			

Kinase Assay	All protein kinase activities were linear with respect to time in every incubation. Assays were performed either manually for 10 min at 30 °C in 50 μ l incubations using [γ -32P]ATP or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 min at ambient temperature in 25 μ l incubations using [γ -33P]ATP. The concentrations of ATP and magnesium acetate were 0.1 mM and 10 mM respectively unless stated otherwise. This concentration of ATP is 5–10-fold higher than the Km for ATP of most of the protein kinases studied in the present paper, but lower than the normal intracellular concentration, which is in the millimolar range. All assays were initiated with MgATP. Manual assays were terminated by spotting aliquots of each incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays were terminated by the addition of 5 μ l of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers were then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity [2].
Cell Research	After 48 h in culture, PCl2D cells are cultured in a test medium containing 30 μ M H-89 for 1 h and then exposed to a fresh medium that contained both 10 μ M forskolin and 30 μ M H-89. Cells are scraped off with a rubber policeman and sonicated in the presence of 0.5 mL of 6% trichloroacetic acid. To extract trichloroacetic acid, 2 mL of petroleum ether is added, the preparation mixed and centrifuged at 3000 rpm for 10 min. After aspiration of the upper layer, the residue sample solution is used for determination [1].
Animal Research	H89 (N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide], di-HCl Salt) (10 mg/kg) suspended in 5% DMSO in saline was administered i.p. two hours before each OVA challenge (or two hours before the last OVA challenge). Control animals received equivalent volumes (200 μl) of 5% DMSO in saline [5].

Solubility Information

Solubility	H2O: < 1 mg/mL (insoluble or slightly soluble)
	DMSO: 60 mg/mL (115.54 mM),Sonication is recommended.
	5% DMSO+95% Saline: 3.16 mg/mL (6.09 mM),Solution.
	(< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9257 mL	9.6287 mL	19.2574 mL
5 mM	0.3851 mL	1.9257 mL	3.8515 mL
10 mM	0.1926 mL	0.9629 mL	1.9257 mL
50 mM	0.0385 mL	0.1926 mL	0.3851 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Page 2 of 3 www.targetmol.com

Reference

Chijiwa T, et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem. 1990 Mar 25;265(9):5267-72. Han J, Wang Y, Qiu Y, et al. Single-cell sequencing unveils key contributions of immune cell populations in cancer-

Han J, Wang Y, Qiu Y, et al. Single-cell sequencing unveils key contributions of immune cell populations in canc associated adipose wasting. Cell Discovery. 2022, 8(1): 1-22.

Cui S, Suo N, Yang Y, et al. The aminosteroid U73122 promotes oligodendrocytes generation and myelin formation. Acta Pharmacologica Sinica. 2023: 1-12.

Zheng N, Liu S, Chen J, et al.SARS-CoV-2 NSP2 as a Potential Delivery Vehicle for Proteins. Molecular Pharmaceutics. 2024

Chen J, Huo X, Li Z, et al.Rare ginsenosides transformed from stems and leaves of Panax ginseng reverse obesity by promoting browning of white fat through PKA/CREB pathway via REGy negative regulation. Journal of Ginseng Research. 2024

Zhang, Hongyan, et al. Intracellular AGR2 transduces PGE2 stimuli to promote epithelial-mesenchymal transition and metastasis of colorectal cancer.. Cancer Letters. 2021

Davies SP, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.

Blazev R, et al. Effects of the PKA inhibitor H-89 on excitation-contraction coupling in skinned and intact skeletal muscle fibres. J Muscle Res Cell Motil. 2001;22(3):277-86.

Pan H, Lin Y, Dou J, et al. Wedelolactone facilitates Ser/Thr phosphorylation of NLRP3 dependent on PKA signalling to block inflammasome activation and pyroptosis. Cell Proliferation. 2020, 53(9): e12868

Hosseini-Zare MS, et al. Effects of pentoxifylline and H-89 on epileptogenic activity of bucladesine in pentylenetetrazol-treated mice. Eur J Pharmacol. 2011 Nov 30;670(2-3):464-70.

Fu T, Chai B, Shi Y, et al. Fargesin inhibits melanin synthesis in murine malignant and immortalized melanocytes by regulating PKA/CREB and P38/MAPK signaling pathways. Journal of Dermatological Science. 2019 Mar 28. pii: 50923-1811(19)30069-6.

Reber LL, et al. The AGC kinase inhibitor H89 attenuates airway inflammation in mouse models of asthma. PLoS One. 2012;7(11):e49512.

Xu C, Zhao W, Huang X, et al. TORC2/3-mediated DUSP1 upregulation is essential for human decidualization. Reproduction. 2021, 1(aop).

Liu M, Yang Y, Tan B, et al. Gαi and Gβγ subunits have opposing effects on dexmedetomidine-induced sedation. European Journal of Pharmacology. 2018 Jul 15;831:28-37

Liu M, Yang Y, Tan B, et al. Gαi and Gβγ subunits have opposing effects on dexmedetomidine-induced sedation[J]. European journal of pharmacology. 2018 Jul 15;831:28-37.

Xu C, Zhao W, Huang X, et al. TORC2/3-mediated DUSP1 upregulation is essential for human decidualization[J]. Reproduction. 2021, 1(aop).

Meng Y, Li W, Hu C, et al. Ginsenoside F1 administration promotes UCP1-dependent fat browning and ameliorates obesity-associated insulin resistance. Food Science and Human Wellness. 2023, 12(6): 2061-2072.

Fu T, Chai B, Shi Y, et al. Fargesin inhibits melanin synthesis in murine malignant and immortalized melanocytes by regulating PKA/CREB and P38/MAPK signaling pathways[J]. Journal of Dermatological Science. 2019 Mar 28. pii: 50923-1811(19)30069-6.

Zhao W, Xu C, Peng L, et al.cAMP/PKA signaling promotes AKT deactivation by reducing CIP2A expression, thereby facilitating decidualization. Molecular and Cellular Endocrinology. 2023: 111946.

Shan G, Bi G, Zhao G, et al.Inhibition of PKA/CREB1 pathway confers sensitivity to ferroptosis in non-small cell lung cancer.Respiratory Research.2023, 24(1): 1-15.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 3 of 3 www.targetmol.com